RT Journal Article
SR Electronic
T1 Breathomics can discriminate between anti IgE-treated and non-treated severe asthma adults
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA1463
DO 10.1183/13993003.congress-2015.OA1463
VO 46
IS suppl 59
A1 Giuseppe Santini
A1 Stefano Di Carlo
A1 Alfredo Benso
A1 Nadia Mores
A1 Paul Brinkman
A1 Salvatore Valente
A1 Paolo Montuschi
A1 Francesco Macagno
A1 Gianfranco Politano
A1 Ariane H. Wagener
A1 Aruna T. Bansal
A1 Hugo H. Knobel
A1 Anton J. Vink
A1 Nicholas Rattray
A1 Marco Santonico
A1 Giorgio Pennazza
A1 Yuanyue Wang
A1 Ildiko Horvath
A1 Ratko Djukanovic
A1 Riccardo Polosa
A1 Stephen J. Fowler
A1 Pascal Chanez
A1 Kian F. Chung
A1 Peter J. Sterk
A1 Paolo Montuschi
A1 U-BIOPRED Study Group
YR 2015
UL http://erj.ersjournals.com/content/46/suppl_59/OA1463.abstract
AB Rationale: Omalizumab, an anti-IgE monoclonal antibody, is indicated in adults with severe persistent allergic asthma. Exhaled molecular markers can provide phenotypic information in asthma.Objectives: Determine whether adults with severe asthma on omalizumab (anti-IgE+) have a different breathprint compared with those who were not on anti-IgE therapy (anti-IgE-) as assessed by eNoses and gas chromatography/mass spectrometry (GC/MS) (breathomics).Methods: This was a cross-sectional analysis of the U-BIOPRED adult cohort. Severe asthma was defined by IMI-criteria [Bel, Thorax 2011]. Anti-IgE+ patients were on a regular treatment with s.c. omalizumab (150-375 mg) every 2-4 weeks. Exhaled volatile compounds trapped on adsorption tubes were analysed by a centralized eNose platform (Owlstone Lonestar, two Cyranose 320, Comon Invent, Tor Vergata TEN), including a total of 190 sensors, and GC/MS. Recursive feature elimination (http://topepo.github.io/caret/rfe.html) was used for feature selection and random forests, more robust to overfitting, for classification.Results: 9 anti-IgE+ (females/males 2/7, age 52.6±16.3 years, mean±SD, 1/2/6 current/ex/nonsmokers, pre-bronchodilator FEV1 70.6±21.1% predicted value) and 30 anti-IgE- patients (18/12 females/males, age 53.2±14.2 years, 0/16/14 current/ex/nonsmokers, pre-bronchodilator FEV1 59.6±30.7% predicted value) were studied. Accuracy of classification is shown in Table 1.View this table:Table 1 Conclusions: Preliminary results suggest that breathomics can distinguish between anti-IgE+ and anti-IgE- severe asthma patients.